

Technology: [Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells](#)

VA ID Number:

Inventor: Arthur Vandenbark

Location: Portland, OR

Topic: Genomics

USPTO Issue Date: 1/26/16

Patent Number: 9,243,051

This patent was assigned by the VA.

Contact

Lee Sylvers, PhD

lee.sylvers@va.gov

202-443-5646

Abstract

The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo.